GlassScriptPhysician profile
Khaldoun Mozahem
NPI 1346730504
$1,966.25
in general payments reported to CMS, 2019-2025
29 companies · $65.90 in 2025
The $65.90 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $359 · 2021: $179 · 2022: $573 · 2023: $328 · 2024: $269 · 2025: $65.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.66 |
| Education | $163.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306.68 | 2021-2025 | |
| Allergan, INC. | $178.03 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $176.05 | 2020-2023 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $142.68 | 2019-2022 | |
| Harmony Biosciences LLC | $114.67 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $99.99 | 2022 | |
| Pfizer INC. | $92.50 | 2023-2025 | |
| Axsome Therapeutics, INC. | $81.13 | 2024 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $77.00 | 2022 | |
| Ucb, INC. | $70.10 | 2020 | |
| Amneal Pharmaceuticals LLC | $60.30 | 2019-2023 | Rytary |
| Livanova USA, INC. | $53.17 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $52.31 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.51 | 2022 | |
| Biogen, INC. | $48.56 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.57 | 2021 | |
| Genentech USA, INC. | $39.61 | 2022-2023 | Ocrevus |
| Biohaven Pharmaceuticals, INC. | $34.78 | 2021 | |
| Lundbeck LLC | $31.70 | 2022-2024 | Vyepti |
| Sk Life Science, INC. | $29.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $28.53 | 2020-2023 | |
| Medtronic, INC. | $26.08 | 2025 | Inceptiv |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.39 | 2019 | |
| Amgen INC. | $22.23 | 2020 | |
| Neurelis, INC. | $17.05 | 2020 | |
| Resmed Corp | $16.68 | 2022 | |
| Celgene Corporation | $16.17 | 2023 | Zeposia |
| Lilly USA, LLC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaldoun Mozahem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.